BPL-003 Efficacy and Safety in Treatment Resistant Depression

This quadruple-masked, randomised, multi-centre Phase II study (n=225) investigates the efficacy and safety of a single intranasal dose of BPL-003, combined with psychological support, in patients with treatment-resistant depression (TRD).

The trial, initiated on September 14, 2023, is scheduled for completion in December 2024. Participants will be divided into low, medium, and high dose groups, with psychological support provided before, during, and after dosing. The primary outcome measure is the change from baseline in the Montgomery-Asberg Depression Rating Scale (MADRS) after 4 weeks, assessing the severity of depressive episodes. Secondary outcome measures include safety assessments, suicidal ideation, and plasma levels of 5-MeO-DMT and its metabolites.

Beckley Psytech Ltd is the sponsor, and the study involves various locations in the United States, Australia, Germany, Poland, and Spain. The study aims to address the pressing issue of TRD and contribute valuable insights to treatment approaches for depression.

Topic Treatment-Resistant Depression Depression
Compound 5-MeO-DMT
Country United States of America Australia Germany Poland Spain
Visit trial

Trial Details



Trial Number

Sponsors & Collaborators

Beckley Psytech
Beckley Psytech is working on getting 5-MeO-DMT to market as the first of a variety of psychedelic medicines.

Data attribution

A large set of the trials in our database are sourced from ClinicalTrials.gov (CTG). We have modified these post to display the information in a more clear format or to correct spelling mistakes. Our database in actively updated and may show a different status (e.g. completed) if we have knowledge of this update (e.g. a published paper on the study) which isn't reflected yet on CTG. If a trial is not sourced from CTG, this is indicated on this page and you can follow the link to the alternative source of information.